Compare CFFN & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | KALV |
|---|---|---|
| Founded | 1893 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.1M | 1.0B |
| IPO Year | 2010 | 2014 |
| Metric | CFFN | KALV |
|---|---|---|
| Price | $7.56 | $26.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.25 | ★ $32.60 |
| AVG Volume (30 Days) | 869.4K | ★ 4.5M |
| Earning Date | 04-29-2026 | 07-09-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | $16,300,000.00 | ★ $50,000,000.00 |
| Revenue This Year | $20.16 | $185.42 |
| Revenue Next Year | $6.62 | $59.23 |
| P/E Ratio | $23.80 | ★ N/A |
| Revenue Growth | 6.54 | ★ 495.66 |
| 52 Week Low | $5.51 | $9.83 |
| 52 Week High | $7.97 | $26.85 |
| Indicator | CFFN | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 74.83 |
| Support Level | $7.47 | $14.56 |
| Resistance Level | $7.85 | N/A |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 17.00 | 98.60 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.